Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

BACKGROUND/AIMS: To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare payer perspective. METHODS: A Markov model simula...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Paul, Annemans, Lieven, Gallagher, Meghan, Hasan, Rafiq, Thomas, Simu, Gairy, Kerry, Knudsen, Martin, Onwordi, Henrietta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329632/
https://www.ncbi.nlm.nih.gov/pubmed/22399690
http://dx.doi.org/10.1136/bjophthalmol-2011-300726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329632/
https://www.ncbi.nlm.nih.gov/pubmed/22399690
http://dx.doi.org/10.1136/bjophthalmol-2011-300726

Ejemplares similares